MX381587B - Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos. - Google Patents

Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos.

Info

Publication number
MX381587B
MX381587B MX2017015294A MX2017015294A MX381587B MX 381587 B MX381587 B MX 381587B MX 2017015294 A MX2017015294 A MX 2017015294A MX 2017015294 A MX2017015294 A MX 2017015294A MX 381587 B MX381587 B MX 381587B
Authority
MX
Mexico
Prior art keywords
receptor
toll
present disclosure
pharmaceutical compositions
agonists
Prior art date
Application number
MX2017015294A
Other languages
English (en)
Spanish (es)
Other versions
MX2017015294A (es
Inventor
Cristiana Guiducci
Robert L Coffman
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Publication of MX2017015294A publication Critical patent/MX2017015294A/es
Publication of MX381587B publication Critical patent/MX381587B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017015294A 2015-05-29 2016-05-23 Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos. MX381587B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US201562168470P 2015-05-29 2015-05-29
US201562169321P 2015-06-01 2015-06-01
US201562169309P 2015-06-01 2015-06-01
US201662276767P 2016-01-08 2016-01-08
PCT/US2016/033817 WO2016196062A1 (en) 2015-05-29 2016-05-23 Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

Publications (2)

Publication Number Publication Date
MX2017015294A MX2017015294A (es) 2018-02-19
MX381587B true MX381587B (es) 2025-03-12

Family

ID=56098419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015294A MX381587B (es) 2015-05-29 2016-05-23 Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos.

Country Status (14)

Country Link
US (3) US9993495B2 (cg-RX-API-DMAC7.html)
EP (2) EP3302502B1 (cg-RX-API-DMAC7.html)
JP (1) JP6792294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102779525B1 (cg-RX-API-DMAC7.html)
CN (1) CN107708706A (cg-RX-API-DMAC7.html)
AU (1) AU2016270782B2 (cg-RX-API-DMAC7.html)
CA (1) CA2987237A1 (cg-RX-API-DMAC7.html)
DK (1) DK3302502T3 (cg-RX-API-DMAC7.html)
ES (2) ES2752063T3 (cg-RX-API-DMAC7.html)
HK (1) HK1251471A1 (cg-RX-API-DMAC7.html)
IL (1) IL255903B (cg-RX-API-DMAC7.html)
MX (1) MX381587B (cg-RX-API-DMAC7.html)
RU (1) RU2017145940A (cg-RX-API-DMAC7.html)
WO (1) WO2016196062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CA2964155A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
JP2022505318A (ja) * 2018-10-18 2022-01-14 ドイチェス クレブスフォルシュンクスツェントルム 吸入用乾燥医薬組成物
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
WO2020128893A1 (en) * 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US11613755B2 (en) * 2019-12-31 2023-03-28 Industrial Technology Research Institute Nucleic acid-drug complex and use thereof
US12686870B2 (en) 2020-01-10 2026-07-21 Sbi Biotech Co., Ltd. TLR9 agonists
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
CN114099535B (zh) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物
EP4267136A4 (en) * 2020-12-23 2025-02-05 Cascade Prodrug Inc. Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
US20250009731A1 (en) 2021-11-08 2025-01-09 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
AU2023209887A1 (en) * 2022-01-21 2024-08-15 Trisalus Life Sciences, Inc. Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
DE60334303D1 (de) * 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DK1992635T3 (da) * 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
CN101134046B (zh) * 2006-09-01 2011-10-05 中国医学科学院药物研究所 Tlr4和tlr9激动剂复方在抑制肿瘤转移中的应用
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Tlr9の合成アゴニスト
CA2836676A1 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
MX2017015311A (es) * 2015-05-29 2018-06-19 Merck Sharp & Dohme Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
CA3020873A1 (en) * 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer

Also Published As

Publication number Publication date
US20190151345A1 (en) 2019-05-23
US9993495B2 (en) 2018-06-12
CN107708706A (zh) 2018-02-16
WO2016196062A1 (en) 2016-12-08
RU2017145940A3 (cg-RX-API-DMAC7.html) 2019-11-26
EP3590518B1 (en) 2024-03-20
DK3302502T3 (da) 2019-10-28
EP3302502A1 (en) 2018-04-11
KR102779525B1 (ko) 2025-03-12
KR20180021700A (ko) 2018-03-05
AU2016270782B2 (en) 2021-08-12
US10369168B2 (en) 2019-08-06
CA2987237A1 (en) 2016-12-08
NZ737488A (en) 2024-12-20
AU2016270782A1 (en) 2017-12-07
US20160346312A1 (en) 2016-12-01
ES2752063T3 (es) 2020-04-02
IL255903B (en) 2021-09-30
HK1251471A1 (zh) 2019-02-01
US20180264023A1 (en) 2018-09-20
ES2987696T3 (es) 2024-11-15
RU2017145940A (ru) 2019-07-02
EP3590518A1 (en) 2020-01-08
JP2018521011A (ja) 2018-08-02
JP6792294B2 (ja) 2020-11-25
IL255903A (en) 2018-01-31
MX2017015294A (es) 2018-02-19
US10111899B2 (en) 2018-10-30
EP3302502B1 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
MX2017015294A (es) Administracion intrapulmonar de agonistas de polinucleotidos del receptor 9 tipo toll para el tratamiento contra el cancer de pulmon.
MX2021006804A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX380777B (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
MX2021013520A (es) Antagonistas de union al eje pd-1 y taxanos para usarse en el tratamiento de cancer.
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
BR112017020336A2 (pt) análogos de nucleosídeos 5?-substituídos
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
CO2017002233A2 (es) Compuestos de aminopiridiloxipirazol
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
PH12017502255B1 (en) Nrf2 regulators
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112017018073A2 (pt) agentes de escoramento de poliolefina de ultra alto peso molecular
MD4643B1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases